EcoDrugPlus

Amiloride-Sensitive Amine Oxidase [Copper-Containing]-Like

Ensembl ID : ENSMLUG00000024819
Gene Symbol: LOC102429483
3 Cross references
226 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSMLUG00000011173
Gene Symbol: APP
2 Cross references
276 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSMLUG00000014191
Gene Symbol: AR
2 Cross references
277 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSMLUG00000012596
Gene Symbol: ACE
2 Cross references
93 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSMLUG00000001873
Gene Symbol: AGTR1
2 Cross references
207 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSMLUG00000004283
Gene Symbol: AGTR2
2 Cross references
191 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSMLUG00000007132
Gene Symbol: APLNR
2 Cross references
171 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSMLUG00000013692
Gene Symbol: APH1A
2 Cross references
137 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSMLUG00000026317
Gene Symbol: APH1B
2 Cross references
190 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSMLUG00000028957
Gene Symbol: APEX1
2 Cross references
212 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s-Type

Ensembl ID : ENSMLUG00000023618
Gene Symbol: LOC102435623
3 Cross references
193 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s-Type-Like

Ensembl ID : ENSMLUG00000026739
Gene Symbol: LOC102429158
3 Cross references
193 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).